These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 17111783)

  • 21. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
    Engler S; Flechtenmacher C; Wiedemann KH; Gugler R; Stremmel W; Kallinowski B
    J Viral Hepat; 2004 Jan; 11(1):60-8. PubMed ID: 14738559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy.
    Vrolijk JM; Bekkering FC; Brouwer JT; Hansen BE; Schalm SW
    J Viral Hepat; 2003 May; 10(3):205-9. PubMed ID: 12753339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.
    Van Vlierberghe H; Leroux-Roels G; Adler M; Bourgeois N; Nevens F; Horsmans Y; Brouwer J; Colle I; Delwaide J; Brenard R; Bastens B; Henrion J; de Vries RA; de Galocsy C; Michielsen P; Robaeys G; Bruckers L
    J Viral Hepat; 2003 Nov; 10(6):460-6. PubMed ID: 14633181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.
    Tassopoulos NC; Tsantoulas D; Raptopoulou M; Vassiliadis T; Kanatakis S; Paraskevas E; Vafiadis I; Avgerinos A; Tzathas C; Manolakopoulos S; Ketikoglou I; Aggelis P; Goritsas K; Giannoulis G; Hatzis G G; Thomopoulos K; Akriviadis E; Sypsa V; Hatzakis A
    J Viral Hepat; 2003 May; 10(3):189-96. PubMed ID: 12753337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.
    Jacobson IM; Gonzalez SA; Ahmed F; Lebovics E; Min AD; Bodenheimer HC; Esposito SP; Brown RS; Bräu N; Klion FM; Tobias H; Bini EJ; Brodsky N; Cerulli MA; Aytaman A; Gardner PW; Geders JM; Spivack JE; Rahmin MG; Berman DH; Ehrlich J; Russo MW; Chait M; Rovner D; Edlin BR
    Am J Gastroenterol; 2005 Nov; 100(11):2453-62. PubMed ID: 16279900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial.
    Sulkowski MS; Felizarta F; Smith C; Slim J; Berggren R; Goodman R; Ball L; Khalili M; Dieterich DT;
    J Acquir Immune Defic Syndr; 2004 Apr; 35(5):464-72. PubMed ID: 15021311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.
    Ogawa E; Furusyo N; Toyoda K; Taniai H; Otaguro S; Kainuma M; Murata M; Sawayama Y; Hayashi J
    BMC Gastroenterol; 2010 Apr; 10():38. PubMed ID: 20398383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
    Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
    Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons.
    Cacopardo B; Nunnari G; Benanti F; Cappellani A; Onorante A; Caltabiano E; Russo R
    Infection; 2009 Jun; 37(3):210-5. PubMed ID: 19139808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
    Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
    J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peginterferon alpha-2b plus ribavirin for chronic hepatitis C virus mixed genotype infection.
    Lin CC; Wu CH; Chen HL; Lin IT; Wang SY; Wang TE; Wang HY; Shih SC; Bair MJ
    Ann Hepatol; 2014; 13(4):350-5. PubMed ID: 24927605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
    Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
    Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.